Can you take Bisacodyl with Ondansetron?
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- bisacodyl
- ondansetron
Drug interactions
Moderate drug interactions
Moderate:
ondansetron bisacodyl
Applies to: ondansetron and bisacodyl
Ondansetron can cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. The risk is increased if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances, such as low blood levels of magnesium or potassium. These electrolyte disturbances can occur with bowel cleansing preparations or excessive use of medications that have a laxative effect, such as bisacodyl. Do not exceed the dose and duration recommended on the product label or prescribed by your doctor. You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether taken together or separately. In addition, you should let your doctor know if you experience signs and symptoms of low magnesium or potassium blood level such as weakness, tiredness, drowsiness, dizziness, confusion, tingling, numbness, muscle pain, cramps, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
bisacodyl multivitamins with minerals
Applies to: bisacodyl
Chronic use of bisacodyl may reduce your body's ability to absorb certain vitamins (A, D, E, and K) and minerals like calcium. To reduce the risk of diminished absorption of multivitamins with minerals, it is best to use bisacodyl only occasionally or for short periods. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
9 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Inflammatory Bowel Disease, and Liver Disease.
Appendicitis
Major:
bisacodyl
Bisacodyl has a major potential interaction with Appendicitis.
The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis. These patients may be candidates for emergency surgery. Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.
Arrhythmia
Major:
ondansetron
Ondansetron has a major potential interaction with Arrhythmia.
ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.
Bleeding Disorder
Major:
bisacodyl
Bisacodyl has a major potential interaction with Bleeding Disorder.
The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures. These preparations may cause irritation, burning sensation, and proctitis.
Gastrointestinal Obstruction
Major:
bisacodyl
Bisacodyl has a major potential interaction with Gastrointestinal Obstruction.
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
Heart Failure
Major:
ondansetron
Ondansetron has a major potential interaction with Heart Failure.
ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.
Hypokalemia
Major:
ondansetron
Ondansetron has a major potential interaction with Hypokalemia.
ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.
Inflammatory Bowel Disease
Major:
bisacodyl
Bisacodyl has a major potential interaction with Inflammatory Bowel Disease.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
Liver Disease
Moderate:
ondansetron
Ondansetron has a moderate potential interaction with Liver Disease.
Ondansetron is extensively metabolized by the liver. The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function. During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported. Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease. The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.
Magnesium Imbalance
Major:
ondansetron
Ondansetron has a major potential interaction with Magnesium Imbalance.
ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.
Report options
More resources
bisacodyl
A total of 276 drugs are known to interact with bisacodyl.
- Bisacodyl is in the drug class laxatives.
- Bisacodyl is used to treat the following conditions:
ondansetron
A total of 375 drugs are known to interact with ondansetron.
- Ondansetron is in the drug class 5HT3 receptor antagonists.
-
Ondansetron is used to treat the following conditions:
- Alcohol Use Disorder (off-label)
- Gastroenteritis (off-label)
- Nausea/Vomiting
- Nausea/Vomiting, Chemotherapy Induced
- Nausea/Vomiting, Postoperative
- Nausea/Vomiting, Radiation Induced
- Obsessive Compulsive Disorder (off-label)
- Postanesthetic Shivering (off-label)
- Pruritus (off-label)
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.